Valeant Pharmaceuticals Reports Second Quarter 2015 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Valeant Pharmaceuticals (VRX) PT to $285 at BMO Capital Following 'Strong and Clean' Quarter
July 24, 2015 7:45 AM EDTBMO Capital analyst Alex Arfaei reiterated an Outperform rating and boosted his price target on Valeant Pharmaceuticals (NYSE: VRX) to $285.00 (from $266.00) following a 'strong and clean quarter.'
Arfaei commented, "quarter. The legacy Valeant business in the US continues to exceed our expectations, driven by the US dermatology and Bausch + Lomb (B+L) businesses, including new product... More
Valeant Pharma (VRX) Misses Q2 EPS by 10c; Boosts FY15 Outlook
July 23, 2015 6:02 AM EDTValeant Pharma (NYSE: VRX) reported Q2 EPS of $2.46, $0.10 worse than the analyst estimate of $2.56. Revenue for the quarter came in at $2.73 million, versus $2.04 million reported last year.
Valeant Pharma sees Q3 2015 EPS of $2.60-$2.70. Valeant Pharma sees Q3 2015 revenue of $2.6-2.8... More
